
New treatments delivering better patient outcomes
Experts at The Christie are working on innovative research projects right now, with funding made possible thanks to supporters of The Christie Charity. This includes projects led by researchers like Dr Sara Valpione, whose work to help patients with oesophageal cancer is focused on biomarkers – biological indicators found in blood, body fluids and tissues that give us information about their cancer.
By understanding more about biomarkers, experts can personalise someone’s treatment specifically to them. Targeted treatments offer patients better outcomes, improved quality of life and fewer side effects.
One huge benefit of the Paterson building is that it’s the home of the National Biomarker Centre (NBC). The Paterson building is connected to The Christie and patient samples can get to NBC’s laboratories for analysis within minutes.
As well as opening up more personalised treatments, experts can also improve the speed and accuracy of diagnosis with more information from biomarkers. Importantly, they could then deliver treatment more quickly.
Another research project currently taking place at The Christie is in the haematology research team, where they’ve been working to improve life expectancy for patients with myeloma.
Dr Emma Searle and her team are trialling a drug for patients with myeloma, who have already had at least 2 types of treatment.
The drug offers another effective option when conventional treatment has stopped working. For patients who feel there’s little hope, there’s a chance to live life to the full, for as long as possible.
These are patients like Jan, who was diagnosed with multiple myeloma in February 2020. After struggling with chemotherapy side effects, Jan started on the myeloma clinical trial in November 2022. Read Jan’s story to find out how the trial drug improved her quality of life.

Researchers at The Christie are also working to reduce the risk of cancer spreading. Consultant Paul Sutton and his team have been testing and developing new treatments to improve treatment outcomes for bowel cancer.
Bowel cancer is the third most common cancer in the UK. Cancers in this area of the body can grow into nearby organs.
Usually, a combination of chemotherapy and radiotherapy is used to shrink the tumour. However, the success rate varies considerably between patients. Research to date suggests a link to the immune system, and this is the focus of Paul Sutton’s innovative research.
Survival outcomes for bowel cancer remain largely unchanged over the last 20 years. Mr Sutton’s research could help patients see a reduced risk of cancer spreading and an increased rate of organ preservation.
Research offers cancer patients better, kinder treatments. Together we are improving their quality of life, as well as giving cancer patients of the future hope.
This is work over and above what the NHS funds. Without The Christie Charity and supporters like you, research projects with the power to save and transform lives simply would not be possible.
It is why you are such a vital part of Team Science – and by donating today, you help make this research work possible.
Together we can help improve the lives of more patients.